Given that the TMC435 deal was struck in 2004 when the drug was only at the pre-clinical stage and Medivir only got $10M up-front, I can't imagine the royalty is that great. Hopefully they are at least due low to mid-double digit royalties, though. Do you have any idea on the exact rate they may be due?
I haven’t researched it, but I would expect the royalty rate to be in the low-to-mid teens. Single-digit royalties are typical for drug-delivery deals and technology-platform licenses, but they are rare for full-fledged NME’s.
Medivir has exclusive rights to market TMC435 in Nordic countries but I assume that is a very small portion of the HCV market and probably not exactly a huge opportunity.
The four Nordic countries (Sweden, Denmark, Norway, Finland) have a combined population of 25M, which is about the same as Texas.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.